JP2013508297A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508297A5 JP2013508297A5 JP2012534411A JP2012534411A JP2013508297A5 JP 2013508297 A5 JP2013508297 A5 JP 2013508297A5 JP 2012534411 A JP2012534411 A JP 2012534411A JP 2012534411 A JP2012534411 A JP 2012534411A JP 2013508297 A5 JP2013508297 A5 JP 2013508297A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- heterocyclic ring
- group
- alkyl
- membered saturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 142
- 125000002837 carbocyclic group Chemical group 0.000 claims description 103
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 82
- 229910052757 nitrogen Inorganic materials 0.000 claims description 68
- 125000000217 alkyl group Chemical group 0.000 claims description 67
- 229910052760 oxygen Inorganic materials 0.000 claims description 67
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 66
- 239000001301 oxygen Chemical group 0.000 claims description 66
- 125000005842 heteroatom Chemical group 0.000 claims description 65
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 61
- 229910052717 sulfur Chemical group 0.000 claims description 61
- 239000011593 sulfur Chemical group 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 54
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 46
- 239000000651 prodrug Substances 0.000 claims description 45
- 229940002612 prodrug Drugs 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 45
- 150000002148 esters Chemical class 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 43
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 125000000304 alkynyl group Chemical group 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 125000003342 alkenyl group Chemical group 0.000 claims description 22
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 229920006395 saturated elastomer Polymers 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 12
- 230000000813 microbial effect Effects 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 206010062255 Soft tissue infection Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 206010040872 skin infection Diseases 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 206010056519 Abdominal infection Diseases 0.000 claims description 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 4
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 125000003725 azepanyl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 4
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- HCUOEKSZWPGJIM-IYNMRSRQSA-N (e,2z)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N\O)\C(N)=O HCUOEKSZWPGJIM-IYNMRSRQSA-N 0.000 claims description 2
- 206010060968 Arthritis infective Diseases 0.000 claims description 2
- 208000031729 Bacteremia Diseases 0.000 claims description 2
- 206010014889 Enterococcal infections Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010058674 Pelvic Infection Diseases 0.000 claims description 2
- 206010035148 Plague Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010058028 Shunt infection Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000022338 anthrax infection Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 2
- 229960003907 linezolid Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010035737 Pneumonia viral Diseases 0.000 claims 1
- -1 esters compound Chemical class 0.000 claims 1
- 208000009421 viral pneumonia Diseases 0.000 claims 1
- 0 CB*N(C=C(C(**F)=C(*NI)N1)C1=N1)C1=O Chemical compound CB*N(C=C(C(**F)=C(*NI)N1)C1=N1)C1=O 0.000 description 242
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- QPVSESRTITWMJP-UHFFFAOYSA-N CC(C)(CCN)Cc1cc(C)ccc1 Chemical compound CC(C)(CCN)Cc1cc(C)ccc1 QPVSESRTITWMJP-UHFFFAOYSA-N 0.000 description 2
- LDMJGQCUOSFHPF-UHFFFAOYSA-N CC(C)c1cc(C(C(F)F)NC2CNC2)cc(CCCCN)c1 Chemical compound CC(C)c1cc(C(C(F)F)NC2CNC2)cc(CCCCN)c1 LDMJGQCUOSFHPF-UHFFFAOYSA-N 0.000 description 2
- KGDJNFIHBXQMCF-UHFFFAOYSA-N CC(C)c1ccc(B(O)OC2CCCN)c2c1 Chemical compound CC(C)c1ccc(B(O)OC2CCCN)c2c1 KGDJNFIHBXQMCF-UHFFFAOYSA-N 0.000 description 2
- FBJQXAYSHCWTBI-UHFFFAOYSA-N CC1=CC(CCCCN)=CCC1 Chemical compound CC1=CC(CCCCN)=CCC1 FBJQXAYSHCWTBI-UHFFFAOYSA-N 0.000 description 2
- VXCSCFNJTAFILF-UHFFFAOYSA-N CC1=CC(CCCCN)CC([N+]([O-])=O)=C1 Chemical compound CC1=CC(CCCCN)CC([N+]([O-])=O)=C1 VXCSCFNJTAFILF-UHFFFAOYSA-N 0.000 description 2
- YVFVIFOKHNYCMN-UHFFFAOYSA-N CCC(C)c1cc(OC(F)(F)F)cc(CC/N=C/N)c1 Chemical compound CCC(C)c1cc(OC(F)(F)F)cc(CC/N=C/N)c1 YVFVIFOKHNYCMN-UHFFFAOYSA-N 0.000 description 2
- UCEVACMVQBCUOC-UHFFFAOYSA-N CCc1cc(Cl)cc(CCCCN)c1F Chemical compound CCc1cc(Cl)cc(CCCCN)c1F UCEVACMVQBCUOC-UHFFFAOYSA-N 0.000 description 2
- CHKYAFWLHBUQIQ-UHFFFAOYSA-N CCc1ccc(CN(CCCN)CCCN)cc1 Chemical compound CCc1ccc(CN(CCCN)CCCN)cc1 CHKYAFWLHBUQIQ-UHFFFAOYSA-N 0.000 description 2
- STSQGDLRGBOTPH-UHFFFAOYSA-N CCc1ccc(CNCCC(NC(NC)=N)F)cc1 Chemical compound CCc1ccc(CNCCC(NC(NC)=N)F)cc1 STSQGDLRGBOTPH-UHFFFAOYSA-N 0.000 description 2
- TZVSZCNNBFSCKI-UHFFFAOYSA-N CCc1ccc(CNCCCN)cc1 Chemical compound CCc1ccc(CNCCCN)cc1 TZVSZCNNBFSCKI-UHFFFAOYSA-N 0.000 description 2
- ZYNZZVIPMBANFL-UHFFFAOYSA-N CCc1cccc(CCC(CN)C(F)(F)F)c1 Chemical compound CCc1cccc(CCC(CN)C(F)(F)F)c1 ZYNZZVIPMBANFL-UHFFFAOYSA-N 0.000 description 2
- VASZKFVIRXYACW-UHFFFAOYSA-N CSc(cc(CCCCN)c(F)c1)c1Cl Chemical compound CSc(cc(CCCCN)c(F)c1)c1Cl VASZKFVIRXYACW-UHFFFAOYSA-N 0.000 description 2
- UOMSUHBIHGELAD-UHFFFAOYSA-N Cc1cc(CC#N)cc(CCCCN)c1 Chemical compound Cc1cc(CC#N)cc(CCCCN)c1 UOMSUHBIHGELAD-UHFFFAOYSA-N 0.000 description 2
- HQQOLNPFXJMZSA-UHFFFAOYSA-N Cc1cc(NS(C)(=O)=O)cc(CCCCN)c1 Chemical compound Cc1cc(NS(C)(=O)=O)cc(CCCCN)c1 HQQOLNPFXJMZSA-UHFFFAOYSA-N 0.000 description 2
- SJTCVXJJAYOJRH-UHFFFAOYSA-N Cc1ccc(CN(CCCN)CCCNC([N]#C)=N)cc1 Chemical compound Cc1ccc(CN(CCCN)CCCNC([N]#C)=N)cc1 SJTCVXJJAYOJRH-UHFFFAOYSA-N 0.000 description 2
- OYDTYQIAYHPHGF-UHFFFAOYSA-N NCCCCc1cccc(C=C(F)F)c1 Chemical compound NCCCCc1cccc(C=C(F)F)c1 OYDTYQIAYHPHGF-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- CCFSRMNNALIMLZ-UHFFFAOYSA-N CC(C)(C)C(CC(C)(C1)NC)CN1NC Chemical compound CC(C)(C)C(CC(C)(C1)NC)CN1NC CCFSRMNNALIMLZ-UHFFFAOYSA-N 0.000 description 1
- WIXHDKLNNBRNJD-UHFFFAOYSA-N CC(C)(C)c1cccc(NI)c1 Chemical compound CC(C)(C)c1cccc(NI)c1 WIXHDKLNNBRNJD-UHFFFAOYSA-N 0.000 description 1
- UGLLVMFACYRYJT-UHFFFAOYSA-N CSc1cc(NI)cc(NI)c1 Chemical compound CSc1cc(NI)cc(NI)c1 UGLLVMFACYRYJT-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25247809P | 2009-10-16 | 2009-10-16 | |
| US61/252,478 | 2009-10-16 | ||
| US31428710P | 2010-03-16 | 2010-03-16 | |
| US61/314,287 | 2010-03-16 | ||
| US35820110P | 2010-06-24 | 2010-06-24 | |
| US61/358,201 | 2010-06-24 | ||
| PCT/US2010/052922 WO2011047319A2 (en) | 2009-10-16 | 2010-10-15 | Antimicrobial compounds and methods of making and using the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016054375A Division JP2016172733A (ja) | 2009-10-16 | 2016-03-17 | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
| JP2017148521A Division JP2018039784A (ja) | 2009-10-16 | 2017-07-31 | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508297A JP2013508297A (ja) | 2013-03-07 |
| JP2013508297A5 true JP2013508297A5 (https=) | 2013-11-07 |
| JP6267863B2 JP6267863B2 (ja) | 2018-01-24 |
Family
ID=44343888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534411A Expired - Fee Related JP6267863B2 (ja) | 2009-10-16 | 2010-10-15 | 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9193731B2 (https=) |
| EP (2) | EP3406613A1 (https=) |
| JP (1) | JP6267863B2 (https=) |
| KR (2) | KR101972992B1 (https=) |
| CN (1) | CN102712647B (https=) |
| AU (3) | AU2010306646B2 (https=) |
| CA (1) | CA2777734A1 (https=) |
| DK (1) | DK2488525T3 (https=) |
| EA (1) | EA201270566A1 (https=) |
| ES (1) | ES2675798T3 (https=) |
| IL (2) | IL219133A (https=) |
| MX (2) | MX349718B (https=) |
| NZ (1) | NZ599291A (https=) |
| PH (1) | PH12016502092A1 (https=) |
| WO (1) | WO2011047319A2 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011047320A2 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
| US9216979B2 (en) | 2009-10-16 | 2015-12-22 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| KR101972992B1 (ko) | 2009-10-16 | 2019-04-29 | 멜린타 서브시디어리 코프. | 항미생물성 화합물 및 이의 제조 방법 및 사용 방법 |
| KR20140065378A (ko) | 2011-04-15 | 2014-05-29 | 멜린타 테라퓨틱스, 인크. | 항미생물 화합물 및 그의 제조 방법과 사용 방법 |
| JPWO2014030743A1 (ja) * | 2012-08-24 | 2016-08-08 | 武田薬品工業株式会社 | 複素環化合物 |
| EP3038623A4 (en) | 2013-09-09 | 2017-04-19 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| KR20160070066A (ko) * | 2013-09-09 | 2016-06-17 | 멜린타 테라퓨틱스, 인크. | 항균 화합물, 및 이의 제조 방법 및 이용 방법 |
| JP6633618B2 (ja) | 2014-08-21 | 2020-01-22 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体 |
| CA2979342A1 (en) * | 2015-03-11 | 2016-09-15 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA44075A (fr) | 2015-12-17 | 2021-05-19 | Incyte Corp | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017193016A1 (en) | 2016-05-06 | 2017-11-09 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| MX2018013545A (es) | 2016-05-06 | 2019-08-14 | Melinta Therapeutics Inc | Antimicrobianos y metodos de preparacion y uso de los mismos. |
| US10934295B2 (en) * | 2016-05-06 | 2021-03-02 | BioVersys AG | Antimicrobials and methods of making and using same |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017205464A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HUE060256T2 (hu) | 2016-06-20 | 2023-02-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018044783A1 (en) | 2016-08-29 | 2018-03-08 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| JP7101678B2 (ja) | 2016-12-22 | 2022-07-15 | インサイト・コーポレイション | 免疫調節剤としての複素環式化合物 |
| US20180179202A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2018288665A1 (en) | 2017-06-19 | 2019-12-19 | Ashoke Bhattacharjee | Antimicrobials and methods of making and using same |
| US20210403473A1 (en) * | 2018-02-21 | 2021-12-30 | BioVersys AG | Antimicrobial compounds and methods of making and using the same |
| SMT202500157T1 (it) | 2018-03-30 | 2025-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| HUE061503T2 (hu) | 2018-05-11 | 2023-07-28 | Incyte Corp | Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok |
| US12152031B2 (en) | 2018-06-06 | 2024-11-26 | BioVersys AG | Biodefense agents |
| WO2019234509A2 (en) | 2018-06-06 | 2019-12-12 | BioVersys AG | Aminomethylamidine and methylamidine antimicrobial compounds |
| MA52873A (fr) * | 2018-06-15 | 2021-04-21 | Galapagos Nv | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies |
| US20240239800A1 (en) * | 2018-12-07 | 2024-07-18 | BioVersys AG | Pyrrolo[2,3-d]pyrimidin-2-one antimicrobial compounds |
| AU2020209170B2 (en) | 2019-01-16 | 2025-09-04 | Curza Global, Llc | Antimicrobial compounds and methods |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| PE20221038A1 (es) | 2019-09-30 | 2022-06-17 | Incyte Corp | Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores |
| CA3160131A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CA3158103A1 (en) * | 2019-11-13 | 2021-05-20 | Curza Global, Llc | Antimicrobial compounds and methods |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| CR20230230A (es) | 2020-11-06 | 2023-07-27 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE3446812A1 (de) * | 1984-12-21 | 1986-06-26 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazoderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| JP2873340B2 (ja) | 1988-04-29 | 1999-03-24 | 武田薬品工業株式会社 | 抗生物質ｔａｎ―１０５７，その製造法および用途 |
| US5208141A (en) * | 1990-10-09 | 1993-05-04 | Konica Corporation | Silver halide color photographic light-sensitive material |
| US5958930A (en) * | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| WO1994026722A1 (en) * | 1993-05-12 | 1994-11-24 | E.I. Du Pont De Nemours And Company | Fungicidal fused bicyclic pyrimidinones |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
| WO1999007685A1 (en) | 1997-08-07 | 1999-02-18 | Research Corporation Technologies, Inc. | Antibiotic for methicillin resistant bacteria |
| DE19838998A1 (de) | 1998-08-27 | 2000-03-09 | Bayer Ag | Neue Naturstoffderivate |
| EP1113008A1 (en) | 1999-12-29 | 2001-07-04 | Pfizer Products Inc. | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents |
| KR100358083B1 (ko) | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
| DE10061538A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Ureido-Dihydropyrimidinone |
| DE10061542A1 (de) | 2000-12-11 | 2002-06-13 | Bayer Ag | Alkanoylamino-pyrimidine |
| DE10061537A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | beta-Alanin-Derivate |
| DE10061541A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Arylamino-Dihydropyrimidinone |
| US6900215B2 (en) * | 2000-12-15 | 2005-05-31 | Merck Sharp & Dohme Ltd. | Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| DE10133277A1 (de) | 2001-07-09 | 2003-01-23 | Bayer Ag | ß-Alanin-Derivate |
| DE10141271A1 (de) | 2001-08-23 | 2003-03-06 | Bayer Ag | Neue Tetrahydro-1,3,5-triazin-2-on-Derivate und ihre Verwendung |
| DE10208256A1 (de) | 2002-02-26 | 2003-09-04 | Bayer Ag | Piperidinouracile |
| WO2004080466A1 (en) * | 2003-03-07 | 2004-09-23 | Ribapharm Inc. | Cytidine analogs and methods of use |
| RU2358975C2 (ru) | 2003-08-26 | 2009-06-20 | Тейдзин Фарма Лимитед | Пирролопиримидиноновые производные |
| NZ544187A (en) * | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| US20100069632A1 (en) | 2006-07-03 | 2010-03-18 | Sk Chemicals Co., Ltd | Salts of pyrrolopyrimidinone derivatives and process for preparing the same |
| WO2008082440A2 (en) | 2006-08-25 | 2008-07-10 | Emory University | Fluorescent nucleoside analogues |
| NZ575365A (en) | 2006-09-07 | 2012-02-24 | Ind Res Ltd | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
| JP2008222557A (ja) * | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| TWI519508B (zh) | 2007-06-12 | 2016-02-01 | Achaogen Inc | 抗菌劑 |
| GB0724342D0 (en) * | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
| KR20090098710A (ko) * | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
| US20100190747A1 (en) | 2009-01-27 | 2010-07-29 | Hideo Suzuki | Fused ring compound and use thereof |
| US20120263646A1 (en) | 2009-10-15 | 2012-10-18 | Guerbet | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
| KR101972992B1 (ko) | 2009-10-16 | 2019-04-29 | 멜린타 서브시디어리 코프. | 항미생물성 화합물 및 이의 제조 방법 및 사용 방법 |
| KR20140065378A (ko) | 2011-04-15 | 2014-05-29 | 멜린타 테라퓨틱스, 인크. | 항미생물 화합물 및 그의 제조 방법과 사용 방법 |
-
2010
- 2010-10-15 KR KR1020177033784A patent/KR101972992B1/ko not_active Expired - Fee Related
- 2010-10-15 MX MX2015017605A patent/MX349718B/es unknown
- 2010-10-15 EP EP18166144.8A patent/EP3406613A1/en not_active Withdrawn
- 2010-10-15 AU AU2010306646A patent/AU2010306646B2/en not_active Ceased
- 2010-10-15 MX MX2012004340A patent/MX2012004340A/es not_active Application Discontinuation
- 2010-10-15 WO PCT/US2010/052922 patent/WO2011047319A2/en not_active Ceased
- 2010-10-15 US US13/501,825 patent/US9193731B2/en active Active
- 2010-10-15 KR KR1020197011312A patent/KR20190044136A/ko not_active Ceased
- 2010-10-15 EP EP10824203.3A patent/EP2488525B1/en not_active Not-in-force
- 2010-10-15 EA EA201270566A patent/EA201270566A1/ru unknown
- 2010-10-15 JP JP2012534411A patent/JP6267863B2/ja not_active Expired - Fee Related
- 2010-10-15 CA CA2777734A patent/CA2777734A1/en not_active Abandoned
- 2010-10-15 NZ NZ599291A patent/NZ599291A/en not_active IP Right Cessation
- 2010-10-15 DK DK10824203.3T patent/DK2488525T3/en active
- 2010-10-15 ES ES10824203.3T patent/ES2675798T3/es active Active
- 2010-10-15 CN CN201080057335.7A patent/CN102712647B/zh not_active Expired - Fee Related
-
2012
- 2012-04-15 IL IL219133A patent/IL219133A/en not_active IP Right Cessation
-
2015
- 2015-10-12 US US14/880,503 patent/US20160031893A1/en not_active Abandoned
-
2016
- 2016-10-20 PH PH12016502092A patent/PH12016502092A1/en unknown
- 2016-12-01 AU AU2016266048A patent/AU2016266048B2/en not_active Ceased
-
2017
- 2017-10-17 IL IL255097A patent/IL255097A0/en unknown
-
2018
- 2018-06-26 AU AU2018204628A patent/AU2018204628A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508297A5 (https=) | ||
| JP2013508299A5 (https=) | ||
| JP2013508298A5 (https=) | ||
| JP2016121171A5 (https=) | ||
| JP2014510788A5 (https=) | ||
| JP2007514782A5 (https=) | ||
| US8324264B1 (en) | Inhibitors of bacterial biofilms and related methods | |
| JP2019532928A5 (https=) | ||
| RU2005100516A (ru) | Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций | |
| JP2003506354A5 (https=) | ||
| JP6678116B2 (ja) | 抗菌剤を含む医薬組成物 | |
| JP2011526283A5 (https=) | ||
| JP2007500707A5 (https=) | ||
| JP2017218457A (ja) | キサントン化合物の誘導体 | |
| TW201028161A (en) | Novel antibacterial agents for the treatment of gram positive infections | |
| WO2015134171A1 (en) | Heteroarylamide inhibitors of tbk1 | |
| TWI641372B (zh) | 使用抗生素治療超重和肥胖患者感染的方法 | |
| US9994547B2 (en) | Heteroarylamide inhibitors of TBK1 | |
| US10023602B2 (en) | Hamamelitannin analogues and uses thereof | |
| JP2025520237A (ja) | ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物 | |
| KR20170032348A (ko) | 저 치환된 폴리믹신 및 이의 조성물 | |
| TW200530255A (en) | 3-pyridiniummethylcefem compound | |
| JP2017507162A (ja) | 抗菌薬を含む医薬組成物 | |
| US20240279247A1 (en) | Prodrugs of boron compounds and their use in treating bacterial infections | |
| CN107400126A (zh) | 新型噁唑烷酮类化合物及其制备方法和在医学上的应用 |